The scientific basis for novel treatments of systemic sclerosis.
In recent years, many potential antifibrotic treatment strategies have emerged from molecular studies of systemic sclerosis. Few biologicals have already entered clinical trials and these may hopefully prove to be effective in this progressive, profibrotic disease.
Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg Universitätstrasse 27, 91054 Erlangen Germany.
Christian
C
Beyer
Jörg Hw
JH
Distler